BackBristol-Myers Squibb Company Ce Overview

Bristol-Myers Squibb Company Ce EBIT

Bristol-Myers Squibb Company Ce's EBIT is $10B, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$0.00

As of Sep 30, 2026

Annual EBIT (TTM)

$10.23B
↑ 2.44% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Bristol-Myers Squibb Company Ce (CELG-RI) FAQ

The latest EBIT for CELG-RI is $10B as of September 2026. That compares with $10B in the prior-year period — up 2.4% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Bristol-Myers Squibb Company Ce's historical trend and sector peers before judging valuation or financial health.

Over the past year, CELG-RI's EBIT moved from $10B to $10B — a 2.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb Company Ce's operating scale or balance-sheet position.

Against its sector companies, CELG-RI currently prints $10B for EBIT, while the sector average sits near $2.4T. That is roughly 99.6% below the sector mean. Large gaps often invite a closer look at Bristol-Myers Squibb Company Ce's growth, margins, and balance sheet.

A EBIT figure of $10B for CELG-RI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting CELG-RI's EBIT ($10B), review year-over-year change from $10B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.